Pharmaceutical

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Jul 1, 2023 - 20:00
[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Read the original article

Tags:

Previous Article

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

Next Article

KP-910 by Kaken Pharmaceutical for Peripheral Neuropathic Pain: Likelihood of Ap...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Xencor gets grant for bispecific antibody for treating ...

Apr 5, 2024

STAT+: FDA’s latest reorganization puts a new emphasis on its investigations

STAT+: FDA’s latest reorganization puts a new emphasis ...

Nov 15, 2023

Signal: Illumina under investigation by SEC over $8bn Grail acquisition

Signal: Illumina under investigation by SEC over $8bn G...

Aug 16, 2023